Research progress of Chinese materia medica in inhibiting malignant biological behavior of lung cancer stem cells
10.3760/cma.j.cn115398-20220808-00092
- VernacularTitle:中药抑制肺癌干细胞恶性生物学行为研究进展
- Author:
Gang TENG
1
;
Rui ZHANG
;
Jing ZHOU
;
Nianzhi ZHANG
Author Information
1. 安徽中医药大学2020级硕士研究生，合肥 230031
- Keywords:
Carcinoma;
Lung cancer stem cells;
Traditional Chinese Medicine;
Biomarkers;
Signaling Pathways;
Review
- From:
International Journal of Traditional Chinese Medicine
2023;45(2):253-257
- CountryChina
- Language:Chinese
-
Abstract:
Chinese materia medica can inhibit the proliferation, invasion, migration and expression of drug-resistant proteins of lung cancer stem cells (LCSCs), and induce apoptosis and delay self-renewal, as well as exert anti-tumor effects by interfering with their ecological niche, immune microenvironment and aerobic glycolysis, etc. The biomarkers involved mainly include CD133, CD44, ALDH and ABCG2, while the related signaling pathways are Wnt/β-catenin, Hedgehog, and Notch. The research on the intervention of LCSCs by Traditional Chinese Medicine (TCM) is generally few, mostly concentrated in basic research, and the selected experimental indicators have a high repetition rate, involving fewer cell types and signaling pathways; there is a relative lack of clinical trials, which lack an organic connection with basic experiments. In the future, the quality of research is expected to be improved, and in-depth study of TCM with anti-lung cancer stem cell effect should be carried out, with the purpose to promote the precise treatment of lung cancer.
